Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Apixaban 5 mg tablets vs Eliquis 5 mg tablets in healthy Thai volunteers under fasting
TCTR20220517003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), pulmonary embolism (PE) and 1 more (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on TCTR20220517003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220517003.